WO2023132738A1 - Composition pour la prévention ou l'atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif - Google Patents

Composition pour la prévention ou l'atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif Download PDF

Info

Publication number
WO2023132738A1
WO2023132738A1 PCT/KR2023/000445 KR2023000445W WO2023132738A1 WO 2023132738 A1 WO2023132738 A1 WO 2023132738A1 KR 2023000445 W KR2023000445 W KR 2023000445W WO 2023132738 A1 WO2023132738 A1 WO 2023132738A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
extracts
composition
skin damage
group
Prior art date
Application number
PCT/KR2023/000445
Other languages
English (en)
Korean (ko)
Inventor
이선희
신유경
김현재
류제식
안혜신
나창선
Original Assignee
코스맥스바이오 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스바이오 주식회사 filed Critical 코스맥스바이오 주식회사
Publication of WO2023132738A1 publication Critical patent/WO2023132738A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • It relates to a composition for preventing or improving skin damage using a plant extract as an active ingredient.
  • Skin aging can be divided into intrinsic aging and extrinsic aging according to factors. Intrinsic aging is known to be caused by changes in physiological functions of the skin epidermis and dermis according to age, and extrinsic aging is known to be caused by changes in physiological functions of the skin caused by environments such as air pollution, exposure to ultraviolet rays, and stress.
  • MMP-1 Microx Metalloproteinase-1
  • hyaluronic acid oxidative stress induced by ultraviolet rays increases free radicals in the body, and MMP-1 (Matrix Metalloproteinase-1), which decomposes collagen, hyaluronic acid ( It can be explained by damage to the skin epidermis and dermis due to the increased activity of hyaluronidase, which decomposes hyaluronic acid.
  • the stratum corneum of the skin exists in the outermost layer of the skin and is in direct contact with the external environment, so it plays an important barrier function to protect our body from external physical and chemical stress.
  • This barrier function is maintained by epidermal homeostasis.
  • Epidermal homeostasis maintains a continuous skin barrier function by forming a skin barrier called the stratum corneum through terminal differentiation through the growth division and cell migration of keratinocytes in the basal layer (Korean J Food.Sci.Technol.43:458-463, 2011).
  • keratinocytes As keratinocytes differentiate, they produce two factors that affect moisturization. First, during differentiation of keratinocytes, the cell membrane is replaced by a structure called a cornified envelope.
  • the keratinocyte membrane is a membrane structure in which various structural proteins including loricrin, involucrin, and filaggrin are cross-linked, providing skin protection against the external environment and evaporating moisture within keratinocytes. (Nat. Rev. Mol. Cell Biol. 6(4):328-340, 2005).
  • keratinocytes maintain a function as a skin barrier while producing Natural Moisturizing Factor (NMF).
  • NMF Natural Moisturizing Factor
  • a protein that is an important source for the production of natural moisturizing factors is filaggrin, which is decomposed into hydrophilic amino acids by CASP 14 to form natural moisturizing factors.
  • Natural moisturizing factors function to maintain skin moisturizing power by providing water holding capacity and moisture absorption in the air (J. Cell Sci. 122:1285-1294, 2009). Therefore, maintaining an appropriate level of natural moisturizing factor in the skin is a very important factor for skin health through the skin barrier function.
  • Plant-derived materials have been used for a long time because they are excellent in terms of safety.
  • the development of functional materials mainly made of plants and herbal ingredients used in the private sector or in oriental medicine is being actively conducted.
  • the present inventors have tried to develop a composition for preventing or improving skin damage.
  • MMP-1 Microx Metalloproteinase-1
  • the secretion of Procollagen type I is increased, and in damaged epidermal cells
  • Filaggrin, Involucrin, Loricrin and Caspase14 By increasing the expression of Filaggrin, Involucrin, Loricrin and Caspase14, it was confirmed that skin damage can be prevented or improved, and the present invention was completed.
  • One aspect is a health functional food composition for preventing or improving skin damage comprising at least one extract selected from the group consisting of extracts of Breea segeta , Buttercup ( Cardamine leucantha ) and Ixeris stolonifera as an active ingredient. is to provide
  • Another aspect is to provide a cosmetic composition for preventing or improving skin damage, comprising at least one extract selected from the group consisting of extracts of wild parsnip, parsley, and crickets, as an active ingredient.
  • Another aspect is to provide a pharmaceutical composition for preventing or treating skin damage comprising at least one extract selected from the group consisting of extracts of wild parsnip, parsley, and crickets, as an active ingredient.
  • Another aspect is to provide a quasi-drug composition for preventing or improving skin damage, comprising, as an active ingredient, one or more extracts selected from the group consisting of extracts of wild parsnip, water parsley, and silverfish.
  • Another aspect is to provide a method for preventing, improving or treating skin damage comprising administering to a subject in need thereof an effective amount of at least one extract selected from the group consisting of extracts of parsley, parsley, and crickets. .
  • One aspect is a health functional food composition for preventing or improving skin damage comprising at least one extract selected from the group consisting of extracts of Breea segeta , Buttercup ( Cardamine leucantha ) and Ixeris stolonifera as an active ingredient.
  • the plant is a perennial plant of the Asteraceae family, and may be a plant specified as an edible part in the food raw materials notified by the Ministry of Food and Drug Safety.
  • the buttercup is a perennial plant of the Cruciferae family, and may be a plant whose leaves are specified as edible parts in food raw materials notified by the Ministry of Food and Drug Safety.
  • the silverfish is a perennial plant of the Asteraceae family, and may be a plant whose roots and leaves are specified as edible parts in food raw materials notified by the Ministry of Food and Drug Safety.
  • the extract may be extracted from at least one selected from the group consisting of the whole plant, root, stem, branch, leaf, seed and fruit of the extracts of A.
  • Whole, part of, or materials derived therefrom of the extracts of the wild parsnip, parsley, and silverfish used in the extraction may be ground or shredded or suitably dried.
  • An extraction method for obtaining the extract may be prepared according to a known extraction method commonly used in the art to which the present invention belongs. Specifically, commonly used extraction methods such as cold precipitation, heat extraction, ultrasonic extraction, filtration, pressure extraction, reflux extraction, supercritical extraction, and electrical extraction may be used, and a conventional extraction device, ultrasonic crushing extractor or fractionator may be used. .
  • the dried or concentrated extract used in the present invention means dried or concentrated by a known method as described above.
  • the extract may be extracted using water, alcohol, or a mixture thereof as a solvent.
  • the alcohol may be a C1 to C6 alcohol, for example a C1 to C4 alcohol.
  • the C1 to C6 alcohol may be methanol, ethanol, propanol, isopropanol, 1,3-propanediol, butanol, pentanol or hexanol.
  • the extraction is 3 to 10 (volume or weight) times the extraction solvent for each extract, for example, 3 to 7 (volume / weight) times, 3 to 5 (volume / weight) times , 5 to 10 (volume / weight) times, or 4 to 10 (volume / weight) times.
  • the solvent may be a mixture of water and alcohol, that is, an aqueous alcohol solution, for example, an aqueous ethanol solution.
  • the alcohol concentration in the alcohol aqueous solution is 1 to 99.5 (v / v)%, 10 to 99.5 (v / v)%, 1 to 70 (v / v)%, 1 to 40 (v / v)%, 5 to 25 (v/v)%, 7 to 20 (v/v)%, 5 to 25 (v/v)%, or 10 to 20 (v/v)%.
  • the extract increases the expression or activity of any one or more selected from the group consisting of Filaggrin, Involucrin, Loricrin and Caspase 14 can
  • the extract may inhibit the expression or activity of MMP-1.
  • the extract may be to increase the expression or activity of procollagen type I (Procollagen type I).
  • the extract is effective in moisturizing the skin by increasing the expression or activity of Filaggrin, Involucrin, Loricrin and/or Caspase 14, and furthermore, it causes skin damage. It has been confirmed that it can be prevented, ameliorated or treated. In addition, it was confirmed that skin damage can be prevented, improved or treated by increasing the expression or activity of procollagen type I and inhibiting the expression or activity of MMP-1.
  • skin damage includes external stimuli, for example, death of human skin cells by ultraviolet rays, skin cell DNA damage, increased reactive oxygen species, increased lipid peroxidation, etc., the symptoms of which include erythema, It may include sunburn, hyperpigmentation, photoaging, skin cancer, and the like.
  • the skin damage may be caused by ultraviolet rays.
  • prevention refers to partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its attendant symptoms, preventing the acquisition or re-acquisition of a disease or disorder, or preventing the occurrence or recurrence of a disease or disorder. Reducing the risk of acquisition.
  • the prevention refers to any action that inhibits or delays the occurrence of a skin damaging disease, disorder, or symptom by administering the composition according to the present invention.
  • the term “improvement” refers to any action that at least reduces a parameter associated with the condition being treated, eg, the severity of a symptom.
  • the extract is 0.0001% to 99.0% by weight relative to the total weight of the composition, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 0.01% to 30% by weight 0.01 wt% to 10 wt%, 0.01 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt%, 0.05 wt% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight % by weight, 0.1% to 10% by weight, 0.1% to 5% by weight, 1% to 50% by weight, 1% to 40% by weight, 2% to 40% by weight, 3% to 30% by weight 4% to 30%, 5% to 30%, 5% to 20%, 5% to 18%, 6% to 15%, 8% to
  • the term "health functional food” refers to a food manufactured and processed by using a specific ingredient as a raw material or by extracting, concentrating, refining, mixing, etc. a specific ingredient contained in a food raw material for the purpose of health supplement. It refers to food designed and processed so that it can sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc.
  • the health functional food composition may perform functions related to prevention and improvement of skin damage caused by fine dust.
  • Examples of foods to which the extract may be added include powders, granules, tablets, capsules, pills, gels, jellies, suspensions, emulsions, syrups, tea bags, leached teas, gums, candies, and formulations selected from the group consisting of health drinks etc., and includes all health foods in the usual sense.
  • the health beverage composition may include various sweeteners, flavoring agents, or natural carbohydrates as additional components, as in conventional beverages.
  • the sweetener may be a natural sweetener or a synthetic sweetener.
  • the natural sweetener may be taumatin or stevia extract, and the synthetic sweetener may be saccharin or aspartame.
  • the natural carbohydrate may be monosaccharide, disaccharide, polysaccharide, xylitol, sorbitol or erythritol.
  • the monosaccharide may be glucose or fructose
  • the disaccharide may be maltose or sucrose.
  • the polysaccharide may be a dextrin or a cyclodextrin.
  • the proportion of the natural carbohydrate may be generally about 0.01 to 10 g, for example, about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
  • the health functional food may include food additives acceptable in food science, and may include appropriate carriers commonly used in the manufacture of health functional food.
  • the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages; and the like.
  • the composition of the present invention may include fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not critical, but is generally selected in the range of 0.01 to 0.1 part by weight per 100 parts by weight of the composition of the present invention.
  • Another aspect provides a cosmetic composition for preventing or improving skin damage, comprising at least one extract selected from the group consisting of extracts of wild parsnip, buttercup, and cactus extract as an active ingredient.
  • the cosmetic composition includes lotion (skin lotion), toner, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, hand sanitizer, foundation, essence, Nutritional essence, packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, suspensions, gels, powders, pastes, mask packs, and can be prepared into formulations including sheets. Compositions of such formulations may be prepared according to conventional methods in the art. The blending amount of the additional ingredients such as the moisturizing agent can be easily selected by those skilled in the art within a range that does not impair the objects and effects of the present invention.
  • the cosmetic composition may further include functional additives and ingredients included in general cosmetic compositions in addition to the active ingredients disclosed herein, and commonly used purified water, thickeners, preservatives, stabilizers, solubilizers, surfactants, carriers, A flavoring agent or a combination thereof may be further included.
  • the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts.
  • Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, UV scattering agents, UV absorbers, coloring agents, perfumes, and the like may be exemplified as the carrier.
  • Compounds/compositions that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, humectant, viscosity modifier, emulsion, stabilizer, UV scattering agent, UV absorber, coloring agent, fragrance, etc. are already known in the art. Since there is, those skilled in the art can select and use an appropriate corresponding material / composition.
  • the cosmetic composition if necessary, sunscreen, antioxidants (butylhydroxyanisole, gallic acid propyl, ellisorbic acid, tocopheryl acetate, butylated hydroxytoluene, etc.), preservatives (methylparaben, butylparaben , propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorant, pH adjuster (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid , sodium succinate, sodium hydroxide, sodium hydrogen phosphate, etc.), humectants (glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin, betaine, glycereth-26, methylglue Seth-20, etc.) and lubricants may be further added.
  • antioxidants butylhydroxyani
  • Another aspect provides a pharmaceutical composition for preventing or treating skin damage comprising, as an active ingredient, at least one extract selected from the group consisting of extracts of wild parsnip, parsley, and cactus.
  • Another aspect provides a method for preventing, ameliorating or treating skin damage comprising administering to a subject in need thereof an effective amount of at least one extract selected from the group consisting of extracts of C.
  • the term "pharmaceutical composition” can refer to a molecule or compound that imparts some beneficial effect upon administration to a subject. Beneficial effects may include enabling diagnostic determination; amelioration of a disease, symptom, disorder or condition; reducing or preventing the occurrence of a disease, condition, disorder or condition; and responding to a disease, symptom, disorder or condition in general.
  • treatment refers to any action that improves or beneficially alters a disease, disorder, or its attendant symptoms.
  • the pharmaceutical composition may be formulated in a formulation selected from the group consisting of tablets, soft or hard capsules, pills, powders, suspensions, syrups, injections and granules.
  • the pharmaceutical composition may be for oral or parenteral administration.
  • the pharmaceutical composition includes conventional fillers, extenders, binders, disintegrants, anti-agglomerates, lubricants, wetting agents, pH adjusters, nutrients, vitamins, electrolytes, alginic acid and its salts, pectic acid and its salts, protective chlorides, glycerin, Perfumes, emulsifiers or preservatives may be included.
  • the pharmaceutical composition may include a pharmaceutically acceptable carrier, examples of which include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, and gelatin.
  • a pharmaceutically acceptable carrier examples of which include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, and gelatin.
  • talc magnesium stearate and mineral oil, propylhydroxybenzoate, It may be at least one selected from the group consisting of talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin and physiological saline.
  • the formulation of the pharmaceutical composition may vary depending on the method of use, and is formulated using a method well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. It can be.
  • Formulations for oral administration include tablets, soft or hard capsules, pills, powders, suspensions, syrups, injections and granules, etc., and these formulations include one or more excipients such as starch, calcium carbonate, sucrose or lactose. , It may be prepared by mixing gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
  • Formulations for parenteral administration may be creams, lotions, ointments, warnings, liquids, aerosols, liquid extracts, elixirs, salivas, sachets, patches, or injections.
  • the method is applicable to any animal, and the animal may include livestock such as cattle, pigs, sheep, horses, dogs, and cats, as well as humans and primates.
  • the dosage of the composition for treatment, prevention, or improvement may be determined in consideration of the administration method, the age, sex, severity of the patient, the degree of absorption of the active ingredient in the body, the inactivation rate, and concomitant drugs, 0.1 mg/kg (body weight) to 500 mg/kg (body weight), 0.1 mg/kg (body weight) to 400 mg/kg (body weight), or 1 mg/kg (body weight) to 300 based on the daily active ingredient It may be administered in mg/kg (body weight), and may be administered once or divided into several times, but is not limited thereto.
  • Another aspect provides a quasi-drug composition for preventing or improving skin damage, comprising, as an active ingredient, one or more extracts selected from the group consisting of extracts of wild parsnip, water parsley, and silverfish.
  • quadsi-drugs refers to textiles, rubber products, or similar products used for the purpose of treating, mitigating, treating or preventing human or animal diseases, weak or non-directly acting on the human body, and not instruments or machines.
  • Products used for the purpose of diagnosing, treating, mitigating, treating, or preventing human or animal conditions or diseases which fall under one of the following categories: It refers to items other than instruments, machines, or devices, and items other than instruments, machines, or devices among items used for the purpose of pharmacologically affecting the structure and function of humans or animals, including external skin products and personal hygiene products. can include
  • the extract When the extract is added to a quasi-drug composition, the extract may be added as it is or used together with other quasi-drug ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the quasi-drug composition is not particularly limited thereto, but may be a personal hygiene product, an external skin preparation, a humidifier filler, a mask, an ointment, or a filter filler.
  • the personal hygiene product may be soap, wet tissue, toilet paper, shampoo, toothpaste, hair care product, air freshener gel or cleansing gel.
  • a composition containing a plant extract according to one aspect inhibits MMP-1 expression and increases the expression of procollagen type I and skin barrier-related factors, thereby effectively preventing or improving skin damage.
  • Figure 1 is a graph showing the cell viability according to the treatment of the extracts of japonica, buttercup or japonica extract in dermal cells damaged by UV-B:
  • Figure 1 (a) is a graph showing the cell viability according to the treatment of each concentration of the extract of chabaengi extract
  • Figure 1 (b) is a graph showing the cell viability according to the concentration of watercress extract
  • Figure 1 (c) is a graph showing the cell viability according to the treatment of each concentration of the extract of the cilia extract.
  • Figure 2 is a graph showing the cell viability according to the treatment of the extracts of japonica, buttercup or japonica extract in epidermal cells damaged by UV-B:
  • Figure 2 (a) is a graph showing the cell viability according to the treatment of each concentration of the extract of chabaengi extract
  • Figure 2 (b) is a graph showing the cell viability according to the concentration of watercress extract
  • Figure 2 (c) is a graph showing the cell viability according to the treatment of each concentration of the extract of the c.
  • Figure 3 is a graph showing the amount of MMP-1 secretion according to the treatment of the dermal cells damaged by UV-B, the extract, the buttercup extract, or the clam extract:
  • Figure 3 (a) is a graph showing the amount of secretion of MMP-1 according to the treatment of each concentration of the extract of chabaengi;
  • Figure 3 (b) is a graph showing the amount of secretion of MMP-1 according to the concentration of the buttercup extract;
  • FIG. 3(c) is a graph showing the secretion amount of MMP-1 according to the treatment of each concentration of the c.
  • Figure 4 is a graph showing the amount of secretion of Procollagen type I according to the treatment of extracts of C. japonica, Buttercup, or Raccoonsis in dermal cells damaged by UV-B:
  • Figure 4 (a) is a graph showing the amount of secretion of Procollagen type I according to the treatment of each concentration of the extract of chabaengi;
  • Figure 4 (b) is a graph showing the secretion amount of Procollagen type I according to the concentration of the buttercup extract;
  • FIG. 4(c) is a graph showing the amount of secretion of Procollagen type I according to the treatment of each concentration of the c.
  • 5 is a graph showing the expression levels of Filaggrin, Involucrin, Loricrin, and Caspase14 according to the treatment of the extract of Chabaengi in epidermal cells damaged by UV-B.
  • the dried product completely dried was pulverized using a homogenizer, and 30 g of the pulverized product was added to 900 g of an extraction solvent in which ethanol and distilled water were mixed at a weight ratio of 3:7. At this time, the mixing ratio of the pulverized material and the extraction solvent was set to 30 times the weight ratio.
  • the extraction solvent mixed with the pulverized product was placed in a shaking water bath and extracted with stirring at 60° C. for 5 hours. Then, insoluble substances were removed from the material obtained by extraction using Whatman (No. 2) extraction solvent filter paper at room temperature.
  • the extracts were concentrated under reduced pressure in a distillation apparatus equipped with a cooling condenser to completely remove the extraction solvent, thereby obtaining extracts of A.
  • Hs68 fibroblasts were cultured in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic at 5% CO 2 and 37°C. And Hs68 fibroblast cells were stabilized in a 24-well plate at a concentration of 8.0 ⁇ 10 4 cells/500 ⁇ l/well for 24 hours. Then, in order to irradiate UV-B, the existing medium was removed, PBS (Phosphate Buffer Solution) was washed, and UV-B was treated with 20 mJ/cm 2 . And each extract of Example 1 was treated at a concentration of 12.5, 25, 50 or 100 ppm and cultured for 24 hours.
  • MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. More specifically, each cell was treated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution to reach a final concentration of 0.5 mg/ml and incubated for 4 hours. After that, the solution was completely removed and the absorbance of the plate dissolved in DMSO (Dimethyl sulfoxide) was measured at 590 nm.
  • DMSO Dimethyl sulfoxide
  • Figure 1 is a graph showing the cell viability according to the treatment of a parsley extract, a parsley parsley extract, or a cactus extract in dermal cells damaged by UV-B.
  • Figure 1 (a) is a graph showing the cell viability according to the treatment of each concentration of the extract of chabaengi extract
  • Figure 1 (b) is a graph showing the cell viability according to the treatment of each concentration of the water parsley extract
  • Figure 1 (c) is a graph showing the cell viability according to the treatment of each concentration of the extract of the c.
  • the extracts of Cabbage, Buttercup, or Raccoons did not show cytotoxicity, and the treatment concentrations of the experimental examples were determined based on the cytotoxicity test.
  • Hacat epidermal cells were cultured in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic at 5% CO 2 and 37°C. Hacat cells were then stabilized in a 96-well plate at a concentration of 1.0 ⁇ 10 4 cells/200 ⁇ l/well for 24 hours. Then, in order to irradiate UV-B, the existing medium was removed, PBS (Phosphate Buffer Solution) was washed, and UV-B was treated at 18 mJ/cm 2 . And each extract of Example 1 was treated at a concentration of 12.5, 25, 50 or 100 ppm and cultured for 24 hours.
  • MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. More specifically, each cell was treated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution to reach a final concentration of 0.5 mg/ml and incubated for 4 hours. After that, the solution was completely removed and the absorbance of the plate dissolved in DMSO (Dimethyl sulfoxide) was measured at 590 nm.
  • DMSO Dimethyl sulfoxide
  • Figure 2 is a graph showing the cell viability according to the treatment of the extract, buttercup extract, or cactus extract in epidermal cells damaged by UV-B.
  • Figure 2 (a) is a graph showing the cell viability according to the treatment of each concentration of the extract of chabaengi extract
  • Figure 2 (b) is a graph showing the cell viability according to the treatment of each concentration of the water parsley extract
  • Figure 2 (c) is a graph showing the cell viability according to the treatment of each concentration of the extract of the c.
  • Hs68 fibroblasts were cultured in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic at 5% CO 2 and 37°C. And Hs68 fibroblast cells were stabilized in a 24-well plate at a concentration of 8.0 ⁇ 10 4 cells/500 ⁇ l/well for 24 hours. Then, in order to irradiate UV-B, the existing medium was removed, PBS (Phosphate Buffer Solution) was washed, and UV-B was treated with 20 mJ/cm 2 . And each extract of Example 1 was treated at a concentration of 12.5, 25, 50 or 100 ppm and cultured for 24 hours. MMP-1 in the supernatant obtained after 24 hours was quantified using an ELISA kit, and the results are shown in FIG. 3 .
  • Figure 3 is a graph showing the amount of MMP-1 secretion according to the treatment of an extract, buttercup extract, or a cactus extract in cells damaged by UV-B treatment.
  • Figure 3 (a) is a graph showing the amount of MMP-1 secretion according to the treatment of each concentration of the extract of chabaengi;
  • Figure 3 (b) is a graph showing the amount of MMP-1 secretion according to the concentration of watercress extract; and
  • FIG. 3(c) is a graph showing the amount of MMP-1 secretion according to the treatment of each concentration of the extract of A.
  • the extract according to one embodiment effectively inhibits the secretion of MMP-1 and is effective in preventing or improving skin damage caused by ultraviolet rays.
  • Hs68 fibroblasts were cultured in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic at 5% CO 2 and 37°C. And Hs68 fibroblast cells were stabilized in a 24-well plate at a concentration of 8.0 ⁇ 10 4 cells/500 ⁇ l/well for 24 hours. Then, in order to irradiate UV-B, the existing medium was removed, PBS (Phosphate Buffer Solution) was washed, and UV-B was treated with 20 mJ/cm 2 . And each extract of Example 1 was treated at a concentration of 12.5, 25, 50 or 100 ppm and cultured for 24 hours. Procollagen type I in the supernatant obtained after 24 hours was quantified using an ELISA kit, and the results are shown in FIG. 4 .
  • Figure 4 is a graph showing the amount of Procollagen type I secretion according to the treatment of an extract, a buttercup extract, or a cactus extract in cells damaged by UV-B treatment.
  • Figure 4 (a) is a graph showing the amount of secretion of Procollagen type I according to the treatment of each concentration of the extract of chabaengi;
  • Figure 4 (b) is a graph showing the amount of Procollagen type I secretion according to the concentration of the buttercup radish extract;
  • FIG. 4(c) is a graph showing the amount of secretion of Procollagen type I according to the treatment of the concentration of the extract of A.
  • the above result means that in the case of the extract according to one embodiment, it is effective in preventing or improving skin damage caused by ultraviolet rays by effectively increasing the amount of secretion of Procollagen type I.
  • Hacat epidermal cells were cultured in DMEM medium containing 10% FBS and 1% antibiotic-antimycotic at 5% CO 2 and 37°C. Hacat cells were then stabilized in a 6-well plate at a concentration of 8.0 ⁇ 10 5 cells/2ml/well for 24 hours. Then, in order to irradiate UV-B, the existing medium was removed, PBS (Phosphate Buffer Solution) was washed, and UV-B was treated at 18 mJ/cm 2 . In addition, the extract of Example 1 was treated at concentrations of 12.5, 25, and 50 ppm and cultured for 24 hours.
  • mRNA was extracted from the cells, synthesized into cDNA, and quantitative real-time PCR was performed using a target template (primer) to finally evaluate the expression levels of Filaggrin, Involucrin, Loricrin, and Caspase14 genes, and the results were analyzed. 5.
  • Figure 5 is a graph showing the expression levels of Filaggrin, Involucrin, Loricrin and Caspase14 derived from UV-B treatment according to the treatment of the extract of Jobengi.
  • Tablets were prepared by mixing the extracts of Example 1 in the component ratios shown in Table 1 below, and tableting according to a conventional tablet manufacturing method. It was confirmed that the prepared tablets were stable under all test conditions of the formulation examples.
  • raw material name unit weight (mg) raw material name unit weight (mg) raw material name unit weight (mg) Chobaengi Extract 50 water parsley extract 50 wormwood extract 50 corn starch 100 corn starch 100 corn starch 100 lactose 100 lactose 100 lactose 100 stearic acid 2 stearic acid 2 stearic acid 2
  • Example 1 The extracts of Example 1 were mixed in the ingredient ratios shown in Table 2 below, and filled into gelatin capsules to prepare soft capsules. The prepared capsules were confirmed to be stable under all test conditions of formulation examples.
  • raw material name unit weight (mg) raw material name unit weight (mg) raw material name unit weight (mg) Chobaengi Extract 50 water parsley extract 50 wormwood extract 50 corn starch 100 corn starch 100 corn starch 100 lactose 100 lactose 100 lactose 100 stearic acid 2 stearic acid 2 stearic acid 2
  • Example 1 The extract of Example 1 was mixed in the ingredient ratio shown in Table 3 below, and filled into a bottle or pouch according to a beverage manufacturing method suitable for taste to prepare a liquid formulation. It was confirmed that the prepared liquid preparation was stable under all formulation example test conditions.
  • raw material name unit weight (g) raw material name unit weight (g) raw material name unit weight (g) raw material name unit weight (g) Chobaengi Extract 2.5050 Buttercup Extract 2.5050 wormwood extract 2.5050 xanthan gum 0.0075 xanthan gum 0.0075 xanthan gum 0.0075 fructooligosaccharide solution 0.7500 fructooligosaccharide solution 0.7500 coconut Flower Extract Powder 1.0500 Coconut Flower Extract Powder 1.0500 Ssanghwa Concentrate 1.5000 Ssanghwa Concentrate 1.5000 Ssanghwa Concentrate 1.5000 Red Ginseng Fragrance 0.0450 Red Ginseng Fragrance 0.0450 Red Ginseng Fragrance 0.0450 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425 Purified water 9.1425
  • Example 1 The extract of Example 1. was mixed in the component ratio shown in Table 4 below, and filled into a three-sided cloth according to a jelly manufacturing method suitable for taste to prepare jelly. The prepared jelly was confirmed to be stable under all formulation test conditions.
  • raw material name unit weight (g) raw material name unit weight (g) raw material name unit weight (g) raw material name unit weight (g) Chobaengi Extract 2.0000 Buttercup Extract 2.0000 wormwood extract 2.0000 food gel 0.3600 food gel 0.3600 food gel 0.3600 carrageenan 0.0600 carrageenan 0.0600 carrageenan 0.0600 calcium lactate 0.1000 calcium lactate 0.1000 calcium lactate 0.1000 sodium citrate 0.0600 sodium citrate 0.0600 sodium citrate 0.0600 complex gold extract 0.0200 complex gold extract 0.0200 complex gold extract 0.0200 Enzymatically Treated Stevia 0.0440 Enzymatically Treated Stevia 0.0440 Enzymatically Treated Stevia 0.0440 fructooligosaccharide solution 5.0000 fructooligosaccharide solution 5.0000 fructooligosaccharide solution 5.0000 fructooligosaccharide solution 5.0000 Red Grape Concentrate 2.4000 Red Grape Concentrate 2.4000 Red Grape Concentrate 2.4000 Red Grape Concentrate 2.4000 Purified water 13.9560
  • composition ratios of Preparation Examples 1 to 4 were generally prepared as formulation examples by mixing suitable ingredients, but the mixing ratio and raw materials may be arbitrarily changed as needed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir ou à atténuer les lésions cutanées, contenant un extrait végétal en tant que principe actif. Une composition comprenant un extrait végétal, selon un aspect, inhibe l'expression de MMP-1 et accroît l'expression du procollagène de type I et des facteurs liés à la barrière cutanée, et peut ainsi être efficacement utilisée dans la prévention ou l'atténuation des lésions cutanées.
PCT/KR2023/000445 2022-01-10 2023-01-10 Composition pour la prévention ou l'atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif WO2023132738A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220003111A KR20230107933A (ko) 2022-01-10 2022-01-10 식물 추출물을 유효성분으로 포함하는 피부 손상 예방 또는 개선을 위한 조성물
KR10-2022-0003111 2022-01-10

Publications (1)

Publication Number Publication Date
WO2023132738A1 true WO2023132738A1 (fr) 2023-07-13

Family

ID=87074049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/000445 WO2023132738A1 (fr) 2022-01-10 2023-01-10 Composition pour la prévention ou l'atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20230107933A (fr)
WO (1) WO2023132738A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120136460A (ko) * 2011-06-09 2012-12-20 원광대학교산학협력단 씀바귀 추출물을 유효 성분으로 함유하는 피부질환의 예방과 치료를 위한 조성물
KR102325393B1 (ko) * 2020-10-05 2021-11-10 한국한의약진흥원 소계 추출물의 생물전환물을 유효성분으로 함유하는 피부 미백용 화장료 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120136460A (ko) * 2011-06-09 2012-12-20 원광대학교산학협력단 씀바귀 추출물을 유효 성분으로 함유하는 피부질환의 예방과 치료를 위한 조성물
KR102325393B1 (ko) * 2020-10-05 2021-11-10 한국한의약진흥원 소계 추출물의 생물전환물을 유효성분으로 함유하는 피부 미백용 화장료 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHN HYE SHIN, KIM HYUN JAE, NA CHANGSEON, JANG DAE SIK, SHIN YU-KYONG, LEE SUN HEE: "The Protective Effect of Adenocaulon himalaicum Edgew. and Its Bioactive Compound Neochlorogenic Acid against UVB-Induced Skin Damage in Human Dermal Fibroblasts and Epidermal Keratinocytes", PLANTS, vol. 10, no. 8, 13 August 2021 (2021-08-13), pages 1669, XP093077235, DOI: 10.3390/plants10081669 *
ANONYMOUS: " What is Jobaengi (subtotal) ? (Breea segeta (Cephalanoplos segetum)", BLOG MEDICINAL HERBS, 26 October 2010 (2010-10-26), XP093077237, Retrieved from the Internet <URL:https://m.cafe.daum.net/alsrkstksdirch/dMTp/1013> [retrieved on 20230830] *
PHOENIX MOUNTAIN: "The Effect of Cardamine leucantha", BLOG NAVER, 16 September 2018 (2018-09-16), XP093077242, Retrieved from the Internet <URL:https://blog.naver.com/ehdyto02/221360084135> [retrieved on 20230830] *

Also Published As

Publication number Publication date
KR20230107933A (ko) 2023-07-18

Similar Documents

Publication Publication Date Title
WO2016047907A1 (fr) Composition contenant des cellules mortes de lactobacillus tyndalisé comme ingrédient actif pour hydrater la peau ou atténuer les rides
US20100323044A1 (en) Abnormal protein removing method
US20210330575A1 (en) Cosmetic composition for skin whitening and wrinkle improvement comprising adventitious root extract of centella asiatica as effective ingredient
WO2017222317A1 (fr) Composition ayant pour effet d&#39;améliorer l&#39;hydratation de la peau, d&#39;éliminer la kératine cutanée, d&#39;améliorer l&#39;élasticité de la peau, d&#39;inhiber l&#39;érythème, d&#39;atténuer les rides cutanées ou d&#39;atténuer le photovieillissement cutané, contenant une ionone ou un sel de celle-ci comme ingrédient actif
KR101509848B1 (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d&#39;artemisia umbelliformis
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l&#39;hydrangénol ou de la phyllodulcine en tant que principe actif
WO2017142265A1 (fr) Composition contenant de l&#39;acide adipique utilisé comme principe actif pour l&#39;atténuation des rides de la peau et l&#39;amélioration de l&#39;élasticité de la peau
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2023132738A1 (fr) Composition pour la prévention ou l&#39;atténuation de lésions cutanées, contenant un extrait végétal en tant que principe actif
KR101481208B1 (ko) 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
KR102577528B1 (ko) 피부 개선용 조성물
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
KR102012366B1 (ko) 아슈와간다 캘러스 추출물을 포함하는 미백용 조성물
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2019164090A1 (fr) Composition contenant un extrait de symplocarpe fétide ou une fraction de celui-ci utilisé comme principe actif pour l&#39;atténuation des rides
KR20160081211A (ko) 유색 보리 추출물을 포함하는 피부 상태 개선용 조성물
WO2015152552A1 (fr) Composition comprenant un extrait d&#39;essence d&#39;absinthe alpine
KR102650192B1 (ko) 스노우베리 과육을 포함하는 화장료 조성물 및 이의 제조방법
WO2021167269A1 (fr) Composition de blanchiment contenant un extrait de noyau de prune en tant que principe actif
KR101072725B1 (ko) 시호 추출물을 유효성분으로 함유하는 조성물
KR102579105B1 (ko) 프로바이오틱스를 이용한 수세미오이 추출물의 효소적 전환을 통한 피부미백 개선, 자외선 차단 및 피부암의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737486

Country of ref document: EP

Kind code of ref document: A1